Haemonetics Corporation $HAE Shares Sold by State of New Jersey Common Pension Fund D

State of New Jersey Common Pension Fund D lowered its stake in Haemonetics Corporation (NYSE:HAE) by 3.0% during the second quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 28,468 shares of the medical instruments supplier’s stock after selling 878 shares during the quarter. State of New Jersey Common Pension Fund D owned about 0.06% of Haemonetics worth $2,124,000 at the end of the most recent quarter.

A number of other large investors also recently bought and sold shares of the stock. Royce & Associates LP lifted its position in Haemonetics by 0.7% in the first quarter. Royce & Associates LP now owns 1,161,296 shares of the medical instruments supplier’s stock valued at $73,800,000 after buying an additional 8,028 shares during the last quarter. Royal Bank of Canada increased its stake in Haemonetics by 2.3% during the first quarter. Royal Bank of Canada now owns 1,075,604 shares of the medical instruments supplier’s stock worth $68,355,000 after purchasing an additional 24,650 shares during the period. Citigroup Inc. increased its stake in Haemonetics by 87.3% during the first quarter. Citigroup Inc. now owns 625,565 shares of the medical instruments supplier’s stock worth $39,755,000 after purchasing an additional 291,574 shares during the period. Charles Schwab Investment Management Inc. increased its stake in Haemonetics by 0.9% during the first quarter. Charles Schwab Investment Management Inc. now owns 556,027 shares of the medical instruments supplier’s stock worth $35,336,000 after purchasing an additional 4,834 shares during the period. Finally, Fort Washington Investment Advisors Inc. OH increased its stake in Haemonetics by 0.3% during the second quarter. Fort Washington Investment Advisors Inc. OH now owns 518,682 shares of the medical instruments supplier’s stock worth $38,699,000 after purchasing an additional 1,596 shares during the period. Institutional investors and hedge funds own 99.67% of the company’s stock.

Wall Street Analysts Forecast Growth

HAE has been the topic of a number of recent research reports. Barrington Research reiterated an “outperform” rating and set a $86.00 price target on shares of Haemonetics in a research note on Tuesday, October 21st. Citigroup cut their price target on shares of Haemonetics from $78.00 to $64.00 and set a “buy” rating on the stock in a research note on Tuesday, October 7th. Raymond James Financial lowered shares of Haemonetics from a “strong-buy” rating to an “outperform” rating and cut their price target for the stock from $105.00 to $78.00 in a research note on Monday, August 11th. JPMorgan Chase & Co. reiterated a “neutral” rating and set a $62.00 price target (down from $85.00) on shares of Haemonetics in a research note on Friday, August 8th. Finally, Weiss Ratings lowered shares of Haemonetics from a “hold (c-)” rating to a “sell (d+)” rating in a research note on Saturday, October 25th. One investment analyst has rated the stock with a Strong Buy rating, seven have assigned a Buy rating, one has issued a Hold rating and two have issued a Sell rating to the company. According to MarketBeat, Haemonetics currently has a consensus rating of “Moderate Buy” and a consensus price target of $75.89.

Haemonetics Stock Down 2.0%

HAE stock opened at $49.38 on Thursday. The company’s 50 day moving average price is $51.48 and its 200 day moving average price is $62.24. The company has a debt-to-equity ratio of 1.04, a quick ratio of 1.04 and a current ratio of 1.72. Haemonetics Corporation has a fifty-two week low of $47.31 and a fifty-two week high of $94.99. The firm has a market capitalization of $2.38 billion, a price-to-earnings ratio of 15.10, a PEG ratio of 0.93 and a beta of 0.37.

Haemonetics (NYSE:HAE) last released its earnings results on Thursday, August 7th. The medical instruments supplier reported $1.10 earnings per share for the quarter, topping analysts’ consensus estimates of $1.01 by $0.09. The firm had revenue of $321.39 million for the quarter, compared to analyst estimates of $305.12 million. Haemonetics had a net margin of 12.14% and a return on equity of 26.64%. The business’s quarterly revenue was down 4.4% compared to the same quarter last year. During the same period in the prior year, the firm earned $1.02 earnings per share. Haemonetics has set its FY 2026 guidance at 4.700-5.00 EPS. On average, equities research analysts anticipate that Haemonetics Corporation will post 4.55 EPS for the current fiscal year.

Haemonetics Company Profile

Haemonetics Corporation, a healthcare company, provides suite of medical products and solutions in the United States and internationally. The company offers automated plasma collection systems, donor management software, and supporting software solutions including NexSys PCS and PCS2 plasmapheresis equipment and related disposables and solutions, as well as integrated information technology platforms for plasma customers to manage their donors, operations, and supply chain; and NexLynk DMS donor management system and Donor360 app.